HA002 - Hatton
Área: 3 - Fisiologia / Bioquimica / Farmacologia

Central antinociceptive action of Botulinum toxin type A and its effects on the glia-neuron cross-talk in a TMJ-rheumatoid arthritis model
Muñoz-Lora VRM, Abdalla HB, Matak I, Dugonjic A, Lackovic Z, Clemente-Napimoga JT, Cury AAB
Pós Graduação Em Odontologia - UNIVERSIDADE GUARULHOS
Conflito de interesse: Não há conflito de interesse

We assessed Botulinum toxin type A (BoNT/A) central enzymatic and antinociceptive activity and its possible influence on the glia-neuron communication using a model of antigen-evoked rheumatoid arthritis (RA) in the temporomandibular joint (TMJ) of rats. Wistar rats were induced to RA in the left TMJ by systemic and intra-articular (i.a) challenges using methylated bovine serum albumin. Then, animals were treated with i.a. unilateral (left TMJ) injection of BoNT/A. Spontaneous and mechanically-evoked nocifensive behaviors were assessed by behavioral nocifensive responses, rat grimace scale, and von Frey filaments. Animals were sacrificed and the trigeminal nucleus caudalis (TNC) was collected to perform: 1) immunohistochemical staining of cleaved SNAP25, c-Fos protein and glial fibrillary acidic protein (GFAP); 2) western blot of microglial P2X7 receptor and CX3 chemokine receptor 1 (CX3CR1); and 3) Elisa of microglial modulators Cathepsin S, Fractalkine and pro-inflammatory cytokines TNF-a and IL-1b. BoNT/A application was associated with the appearance of truncated SNAP-25 in the sensory TNC. BoNT/A reduced spontaneous and evoked nociceptive behaviors, bilateral c-Fos expression, and markers of neuronal and glial activation.
The antinociceptive activity of BoNT/A is associated with its ability to transport to upper sensory regions and reduce neuronal and glial cells activation. BoNT/A might be useful as a central acting and neuromodulatory drug for chronic pain conditions. However, BoNT/A effects on glial cells should be carefully explored.
(Apoio: FAPs - FAPESP  N° 2017/07741-7  |  FAPs - BEPE-FAPESP  N° 2018/13575-5  |  CAPES  N° 001)

---

HA005 - Hatton
Área: 4 - Ortodontia

Upper airway changes in miniscrew-anchored maxillary protraction with hybrid and hyrax expanders: a randomized clinical trial
Miranda F, Pugliese FS, Massaro C, Bastos JCC, Santos AM, Janson G, Palomo JM, Garib D
Odontopediatria, Ortodontia e Sc - UNIVERSIDADE DE SÃO PAULO - BAURU
Conflito de interesse: Não há conflito de interesse

The aim of this study was to compare the upper airway space changes after miniscrew-anchored maxillary protraction with hybrid and conventional hyrax expanders. The sample comprised 40 Class III malocclusion growing patients that were randomized into two groups of miniscrew-anchored maxillary protraction. The group HH was treated a hybrid hyrax appliance in the maxilla and two miniscrews distally to the canines in the mandible. Class III elastics were used from the maxillary first molar to the mandibular miniscrews until anterior crossbite correction. The group CH was treated with a similar protocol except for the conventional hyrax expander in the maxilla. CBCT was obtained before (T1) and after 12 months of therapy (T2). The shape and size of upper airway were assessed. Intergroup comparisons were performed using t tests (P<0.05). The group HH was composed by 13 patients (6 female, 7 male) with a mean age of 10.42 years. The group CH was composed by 15 patients (5 female, 7 male) with a mean age of 11.38 years. Good reproducibility was found for all measurements. Anteroposterior and transverse increases of the upper airway were found for both groups. The oropharynx and the most constricted area increased similarly in both groups.
Maxillary protraction using miniscrews as anchorage produced an increase in the upper airways. No differences in upper airway changes were observed using protraction anchored on hybrid or conventional hyrax expanders.
(Apoio: FAPs - FAPESP  N° 2017/04141-9   |  FAPs - FAPESP  N° 2017/24115-2  |  FAPs - FAPESP  N° 2019/03175-2)

---